In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

At Merck, Business Development As Usual?

Executive Summary

Merck's newly appointed SVP for world-wide licensing, C. David Nicholson, outlines the Big Pharma's dealmaking priorities at Elsevier Business Intelligence's February BIO-Windhover Pharmaceutical Strategic Outlook meeting.
Advertisement

Related Content

Merck Adds Flagship To Its Venture Fund Network
Meet Merck’s Dealmaker: A Conversation With Roger Pomerantz
Merck’s Capital Idea: Pharma’s Latest Attempt to Get Closer to VCs
Merck's Capital Idea: Industry's Latest Push to Strengthen VC Ties
Merck's Capital Idea: Industry's Latest Push to Strengthen VC Ties
Pfizer/Washington U. Tie-Up Involves Reprofiling Of Existing Compounds
AZ and Merck: Moving Forward Cautiously
New Frontiers in Pharma R&D Investment
New Frontiers in Pharma R&D Investment
Merck Buys Schering-Plough -- and Time

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003453

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel